CAMBRIDGE,
Mass., Dec. 19, 2024 /PRNewswire/ -- MetaVia
Inc. (Nasdaq: MTVA), a clinical-stage biotechnology
company focused on transforming cardiometabolic diseases, today
announced that it will participate as a Sponsor and Exhibitor at
the upcoming, 9th Annual MASH-TAG 2025 Conference. The
company's participation follows the recent release of positive
top-line 16-week results from the two-part Phase 2a clinical trial
of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119)
agonist, in patients with presumed metabolic dysfunction-associated
steatohepatitis (MASH). The MASH-TAG Conference is taking place
January 9-11 at the Chateaux Deer
Valley in Park City, Utah. Members
of MetaVia's management and clinical team will be available in the
Exhibit Hall at the Conference to discuss the results of the Phase
2a clinical trial of DA-1241.
About MetaVia
MetaVia Inc. is a
clinical-stage biotechnology company focused on transforming
cardiometabolic diseases. The company is currently developing
DA-1726 for the treatment of obesity, and is developing DA-1241 for
the treatment of Metabolic Dysfunction-Associated Steatohepatitis
(MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that
functions as a glucagon-like peptide-1 receptor (GLP1R) and
glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring
gut hormone that activates GLP1R and GCGR, thereby decreasing food
intake while increasing energy expenditure, thus potentially
resulting in superior body weight loss compared to selective GLP1R
agonists. DA-1241 is a novel G-protein-coupled receptor 119
(GPR119) agonist that promotes the release of key gut peptides
GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated
a positive effect on liver inflammation, lipid metabolism, weight
loss, and glucose metabolism, reducing hepatic steatosis, hepatic
inflammation, and liver fibrosis, while also improving glucose
control.
For more information, please visit
www.metaviatx.com.
Contacts:
MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/metavia-to-participate-in-the-9th-annual-mash-tag-2025-conference-after-releasing-positive-top-line-results-from-its-phase-2a-clinical-trial-of-da-1241-in-patients-with-presumed-mash-302335535.html
SOURCE MetaVia Inc.